anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses a heteropoly acid 5-fluorouracil salt anti-tumor drug and a synthetic method thereof, belongs to a chemical synthetic drug and a synthetic method thereof and relates to a heteropoly acid 5-fluorouracil salt chemical drug and a synthetic method thereof. 5-fluorouracil is an anti-metabolism drug and inhibits tumor cells and duplicates the desired metabolic pathway by mainly inhibiting folic acid, purine, pyridine and pyrimidine nucleoside in DNA synthesis; thereby, the tumor cells die. However, the drug has serious first pass effect, and the therapeutic dose is similar to the toxicity dose, namely that the side effect is strong. The present invention carries out the chemical modification on the 5-fluorouracil by using the characteristics of a heteropoly compound, utilizing molecular self-assembly and an organic-inorganic hybridization method; thereby, an anticancer drug with a general formula which is A[x]B[y][X[j]M[12-m]O[40]]. nH2O(POM-Fu)is synthesized. The drug has high anti-tumor activity, low side effect and low price.
The medicament information storage section stores a plurality of types of drug codes respectively assigned to each medicament. The slip information storage section stores, for each use of a slip for notifying information of the medicament used at a medical site, information of the type of drug codes required for the use of the slip. The specifying module specifies the medicament used at the medical site. The registration module registers information relating to the medicament specified by the specifying module. The creation module acquires the drug code of the medicament registered by the registration module for each slip having different use from the medicament information storage section to create slips for different uses based on the information stored in the slip information storage section. The output module outputs the slips created by the creation module for different uses.
Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent chronic liver disease globally. Non-alcoholic steatohepatitis (NASH) represents an extremely progressive form of NAFLD, which, without timely intervention, may progress to cirrhosis or hepatocellular carcinoma. Presently, a definitive comprehension of the pathogenesis of NAFLD/NASH eludes us, and pharmacological interventions targeting NASH specifically remain constrained. The aetiology of NAFLD encompasses a myriad of external factors including environmental influences, dietary habits and gender disparities. More significantly, inter-organ and cellular interactions within the human body play a role in the development or regression of the disease. In this review, we categorize the influences affecting NAFLD both intra- and extrahepatically, elaborating meticulously on the mechanisms governing the onset and progression of NAFLD/NASH. This exploration delves into progress in aetiology and promising therapeutic targets. As a metabolic disorder, the development of NAFLD involves complexities related to nutrient metabolism, liver-gut axis interactions and insulin resistance, among other regulatory functions of extraneous organs. It further encompasses intra-hepatic interactions among hepatic cells, Kupffer cells (KCs) and hepatic stellate cells (HSCs). A comprehensive understanding of the pathogenesis of NAFLD/NASH from a macroscopic standpoint is instrumental in the formulation of future therapies for NASH.
Provided are mutant class III receptor tyrosine kinases (RTKIII) comprising a mutation at the amino acid residue corresponding to the conserved cysteine at residue 432 (C432) or 439 (C439) of a mouse colony-stimulating factor (1) receptor (CSF-IR) precursor having the amino acid sequence of SEQ ID NO: 1, where the mutation is a replacement of the cysteine with an amino acid having an uncharged polar R group. Also provided are mutant RTKIIIs comprising a tyrosine to phenylalanine mutation. Additionally provided are extracellular domains of the above-identified mutant RTKIIIs comprising cysteine to serine mutations. Further provided are stable cell lines of macrophages lacking a native CSF-IR. Also provided are isolated nucleic acids encoding any of the above-described mutant RTKIIIs or extracellular domains. Vectors comprising those nucleic acids are also provided. Additionally provided are methods of preparing the above-identified stable cell lines. Methods of treating a mammal comprising administering the above described extracellular domain to the mammal are also provided.
This research proposal aims to test the feasibility, acceptability and efficacy of SKY (Sudarshan Kriya Yoga) program, a mind-body intervention, as an adjuvant therapy for people suffering with opioid use disorder (OUD), in Columbus, Ohio. Previous research carried out in India in 2015, has demonstrated that SKY significantly improved the quality of life among people with OUD, however, the suitability, acceptability of SKY program has not been tested among American population. SKY differs from mindfulness and other meditation processes in that, it is a more physiological, rather than cognitive process. It involves controlled breathing techniques that can be easily mastered, and do not require mental effort. The investigator's goals are to a) DEMONSTRATE the feasibility, acceptability and efficacy of SKY program as an adjuvant therapy for American population suffering with OUD. Studies will be carried out in OUD subjects at Mary Haven clinic in Columbus. The efficacy of SKY will be measured using psychometric questionnaires. Feasibility and acceptability will be measured by attendance and attrition.
This group will receive routine recommendations by the pediatrician, including specific lifestyle advises. In addition, a 8-week resistance exercise training program will be performed.
A standard absorbent dressing is placed on the radial access site, following the transradial angiographic procedure. A radial compression device is then applied to secure patent haemostasis, once the radial sheath is removed. The compression device remains in place for a minimum of 2 hours, as per protocol. This is the standard radial care currently in use at Liverpool Heart and Chest Hospital.
Patients undergo verbal counseling. Patients also complete questionnaires at 2 weeks, 6 and 12 months.
There are currently very few practical or reproducible model systems which recapitulate the metastatic process well. CTCs are important for the development of metastases and there is interest in isolating and culturing them ex vivo to better characterize their biology, metastatic potential, and response to different therapies. The investigators have previously demonstrated efficient capture and enumeration of CTCs in 4 unique patient cohorts (metastatic prostate and locally advanced rectal, cervical and head and neck cancers) in the investigators prospective clinical study, LCCC 1408 (Investigation of Circulating Tumor Cells from Cancer Patients Undergoing Radiation Therapy). However, CTCs are difficult to culture with conventional methods. The investigators propose to culture CTCs using novel decellularized tissue matrices. Blood will be collected from cancer patients with metastatic solid tissue tumors prior to starting definitive or palliative radiotherapy. The investigators will then isolate CTCs and attempt to grow them on various decellularized matrices. If this study is successful and feasibility is demonstrated, important pilot information will also be gathered which will then be used in power and sample size considerations for future CTCs studies.
PROBLEM TO BE SOLVED: To provide a side surface light-emitting two-chip semiconductor light- emitting device, which can be miniaturized by reducing the size of a substrate. SOLUTION: This side surface light-emitting two-chip semiconductor light- emitting device 10 contains a substrate 12. Leads 18a and 18b are formed on one main surface 12a of the substrate 12, and leads 18c and 18d are formed on the other main surface. The leads 18a and 18c are connected on a side surface 12c of the substrate 12, and the leads 18b and 18d are formed, being stretched as far as the side surface 12c. Since bonding patterns are formed on both surfaces of the substrate 12, the size of the substrate can be reduced. LED chips 20a and 20b, which radiate different colors are bonded on both of the surfaces of the substrate 12.  By applying a voltage to, at least one from among a part between an external connection electrodes 24a and 24b, and a part between an external connection electrodes 24a and 24c, different colors can be generated selectively, and a mixed color can be emitted.
PROBLEM TO BE SOLVED: To obtain an acne-treating composition containing a hydroxypyridone compound or its salt and a sebum secretion inhibitor as active ingredients, not having side effects such as irritation, and capable of effectively treating the acne. SOLUTION: This acne-treating composition contains (A) a 1-hydroxy-2- pyridone compound of the formula (R1 is a 1-17C alkyl, a 2-17C alkenyl, a 5-8C cycloalkyl, etc.; R2 is H, a 1-4C alkyl, a 2-4C alkenyl, an alkinyl, a halogen, phenyl, etc.,) or its salt and (B) a sebum secretion inhibitor (preferably an extract of a leguminous plant) as active ingredients. The component A includes 1-hydroxy-6-methyl-2-pyridone. The component B is obtained from a leguminous plant such as Glycyrrhiza glabra or Glycyrrhiza uralensis as a raw material. The content of the component B is 0.005-20%, preferably 0.05-10%, based on the whole amount of the composition.
Participants with a diagnosis with migraine who currently meet criteria for episodic migraine (migraine with headaches that occur on fewer than 15 days per month) will be recruited from local providers. After an initial screening, eligible participants will complete 30 days of monitoring 3 times daily on an electronic headache diary (a smartphone app) to confirm study eligibility. Participants whose eligibility is confirmed will complete an additional 2 months (60 days) of monitoring headache activity and adherence to acute and preventive (medication and behavioral) strategies recommended for people with migraine. Participants who show suboptimal adherence during the first 3 months of monitoring (\<50% of eligible days) will be eligible to continue to the intervention component of the study. Participants who choose to continue in the study will be randomized to receive a tailored clinical decision support tool or education intervention, both delivered through the smartphone app. Participants will continue to self-monitor, with the intervention components active, for 3 months.
PURPOSE: To develop a PRO assessment of multidimensional cancer-related fatigue based on the PROMIS fatigue assessments.
METHOD: Cancer patients reporting fatigue were recruited from a comprehensive cancer care center and completed a survey including 39 items from the PROMIS Cancer Item Bank-Fatigue. Component and factor structures of the fatigue items were explored with Monte Carlo parallel factor and Mokken analyses, respectively. Psychometric properties were determined using item response theory, ensuring unidimensionality, scalability, and item independence.
RESULTS: Fatigue scores from a sample of 333 fatigued cancer patients (mean age = 59.50, SD = 11.62, 67% women) were used in all scale development analyses. Psychometric analyses yielded 3 dimensions: motivational fatigue (15 items), cognitive fatigue (9 items), and physical fatigue (9 items). The subscales showed strong unidimensionality, were scalable, and were free of differential item function. Confirmatory factor analyses in a new sample of 182 patients confirmed the findings.
CONCLUSION: The resulting 33-item PROMIS multidimensional cancer-related fatigue (mCRF) form provides a novel measure for the assessment of the different dimensions of cancer-related fatigue. It is the only multidimensional scale specific for cancer patients that has been developed using modern psychometric approaches. With its 3 dimensions (motivational, cognitive, and physical fatigue), this scale accurately captures the fatigue experienced by cancer patients, allowing clinicians to optimize fatigue management and improve patient care. The scale could also advance research on the nature and experience of cancer-related fatigue.
Successful implementation of clinical decision support tools is rare, the key barrier being the lack of user involvement during development. Following the idea, development, exploration, assessment, long-term follow-up (IDEAL) framework, this study aims to provide early insights into the current challenges, clinical processes, and priorities when developing new decision support tools in cardiac surgery. Using a qualitative approach, semi-structured interviews were conducted with cardiac anesthetists and surgeons from three Scottish cardiac centers. Thematic analysis identified adverse postoperative outcomes, ageing cardiac patient population and changing surgical procedures to be the main challenges in cardiac surgery. Existing risk prediction tools were largely not used due to a perceived lack of utility and validation. This study underscores the need to shift focus towards predicting postoperative complications, instead of mortality. It emphasizes the importance of early collaboration with clinical experts and stakeholders in developing decision support systems that are fit for purpose. By identifying the priorities of cardiac clinicians, the study lays the groundwork for developing clinically meaningful prediction models.
The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
Non-invasive brain stimulation techniques allow targeted modulation of brain regions and have emerged as a promising tool for vision rehabilitation. This review presents an overview of studies that have examined the use of non-invasive brain stimulation techniques for improving vision and visual functions. A description of the proposed neural mechanisms that underpin non-invasive brain stimulation effects is also provided. The clinical implications of non-invasive brain stimulation in vision rehabilitation are examined, including their safety, effectiveness, and potential applications in specific conditions such as amblyopia, post-stroke hemianopia, and central vision loss associated with age-related macular degeneration. Additionally, the future directions of research in this field are considered, including the need for larger and more rigorous clinical trials to validate the efficacy of these techniques. Overall, this review highlights the potential for brain stimulation techniques as a promising avenue for improving visual function in individuals with impaired vision and underscores the importance of continued research in this field.
The invention belongs to the field of biological medicine, and particularly relates to a VHH nanobody targeting TSLP and application thereof, wherein the nanobody specifically comprises a complementarity determining region CDR1-3 of a VHH chain shown in SEQ ID NO. 4. Further, the VHH chain in the nanobody contains a CDR1 having the sequence shown in SEQ ID NO.1, a CDR2 having the sequence shown in SEQ ID NO.2, and a CDR3 having the sequence shown in SEQ ID NO. 3. The TSLP nanobody disclosed by the invention can be combined with TSLP antigens of human and monkey with high specificity. And is capable of blocking TSLP and its receptor binding, thereby blocking downstream signaling pathways, blocking TSLP stimulating PBMCs to secrete cofactors. It is hopeful to develop a novel inhalation preparation targeting TSLP.
VAGINAL CONTRACEPTIVE                           Abstract The present invention encompasses devices which are used in the vagina to deliver spermicidal sur-factants.  These devices can be inserted by the user, and do not require insertion by a physician as, for example, in the case of intrauterine contraceptive devices.  By virtue of their unique construction and shape, the devices herein are foldable for easy in-sertion.  Once in position at the cervical os, the devices open to "cap" the os and remain in position, even during intercourse, so that access of the spermi-cidal surfactant source to the cervical os is not interrupted.  The devices are designed to remain comfortably in the vagina during the time between menstrual periods to provide desirable, prolonged release of a spermicidal surfactant, and their con-struction and shape facilitate retention therein while minimizing awareness and discomfort.  An effective between-period contraceptive device is thereby provided.
<P>PROBLEM TO BE SOLVED: To provide a method for producing an artificial erythrocyte with which the artificial erythrocyte is produced under mild conditions and even deterioration of hemoglobin is prevented and to provide the artificial erythrocyte produced by the method.  <P>SOLUTION: The artificial erythrocyte is obtained as follows. A visible light-crosslinkable substance such as an eosinized gelatin, a hydrogen donor such as a reducing sugar and hemoglobin are added to a lipophilic liquid and dispersed. The resultant dispersion is then irradiated with visible light to photo-crosslink and gel the dispersed particles. Thereby, the artificial erythrocyte composed of the gelled particles is prepared.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Participants received a single subcutaneous dose of denosumab on day 1. Doses included 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg.
PULMICORT RESPULES is supplied in sealed aluminum foil envelopes containing one plastic strip of five single-dose RESPULES ampules together with patient instructions for use. There are 30 RESPULES ampules in a carton. Each single-dose RESPULES ampule contains 2 mL of sterile liquid suspension. 

PULMICORT RESPULES is available in three strengths, each containing 2 mL:

NDC 54868-5774-0 0.25 mg/2 mL

NDC 54868-5621-0 0.5 mg/2 mL  


  


PULMICORT RESPULES should be stored upright at controlled room temperature 20-25°C (68-77°F) [see USP], and protected from light. When an envelope has been opened, the shelf life of the unused RESPULES ampules is 2 weeks when protected. After opening the aluminum foil envelope, the unused RESPULES ampules should be returned to the aluminum foil envelope to protect them from light. Any opened RESPULES ampule must be used promptly. Gently shake the RESPULES ampule using a circular motion before use. Keep out of reach of children. Do not freeze.
Systems and methods for clinician decision support during mechanical ventilation of a patient comprise evaluating a shape and/or characteristics of a waveform to detect an anomaly. While mechanical ventilators are equipped with a number of alarms and alerts when monitored patient data breaches various alarm thresholds, some anomalies in patient data may go unnoticed by clinicians. These anomalies, however, may provide relevant information regarding patient condition. Accordingly, in response to detecting an anomaly, the ventilator captures at least a portion of the waveform. The waveform capture, which may be annotated with various labels and educational information, may be reviewed by a clinician to obtain additional information regarding the anomaly. In this way, clinicians may be trained to recognize and address anomalies associated with waveform data and thereby be armed with information to optimize patient-ventilator interaction.
AOSEPT Plus and AOCup lens case used as instructed with habitual contact lenses for 90 days. It is expected that the habitual contact lenses will be worn for at least 8 hours per day for at least 5 days per week during study participation.
The control group received no intervention during the intervention period. However, they will participate in surveys at three time points (before the intervention, 3 months after the intervention and one year after the intervention). Once their final assessment is completed, controls will be offered the opportunity to take the MHFA training course, if they wish.
BACKGROUND AND AIM: Moderate and late preterm infants (MLPTI) (gestational age 32 0/7-36 6/7 weeks), are at risk for suboptimal growth. This study evaluated adherence to nutritional recommendations until 6 months corrected age (CA), growth until 2 years CA, and associations between nutritional intake and growth until 2 years CA.
METHODS: We prospectively collected nutritional intakes from 100 MLPTI during the first week of life and at 6 weeks, 3 months, and 6 months CA. Anthropometry was assessed at birth, discharge, term age, and at 6 weeks, 3 months, 6 months, 1 year, and 2 years CA.
RESULTS: On day 7, <40% reached nutritional recommendations. Thereafter, >80% reached protein recommendations until 6 months of life, but <60% reached energy recommendations. Weight z-scores increased from -0.44 at term-age to 0.59 at 3 months CA, but declined to -0.53 at 2 years CA on the TNO curves. No significant associations were found between nutritional intake and growth until 2 years CA.
CONCLUSION: No associations were demonstrated between nutritional intakes and growth until 2 years CA, despite not reaching recommended intakes. Despite high efforts to optimize growth, MLPTI find their own growth curve in the first 2 years of life.
IMPACT: This research is pioneering in identifying how nutrition influences growth in moderate and late preterm infants (MLPTI) up to 2 years corrected age (CA). MLPTI often do not meet the recommended protein and energy intake in their first week of life, suggesting that current guidelines might be too high. No association was demonstrated between nutritional intake and growth of MLPTI in the first 2 years of life. Initially, MLPTI show an increase in weight z-scores from term age up to 3 months CA but experience a decline in weight z-scores at 2 years CA, according to TNO growth charts.
Pancreatic ductal adenocarcinoma (PDAC) manifests diverse molecular subtypes, including the classical/progenitor and basal-like/squamous subtypes, with the latter known for its aggressiveness. We employed integrative transcriptome and metabolome analyses to identify potential genes contributing to the molecular subtype differentiation and its metabolic features. Our comprehensive analysis revealed that adrenoceptor alpha 2A (ADRA2A) was downregulated in the basal-like/squamous subtype, suggesting its potential role as a candidate suppressor of this subtype. Reduced ADRA2A expression was significantly associated with a high frequency of lymph node metastasis, higher pathological grade, advanced disease stage, and decreased survival among PDAC patients. In vitro experiments demonstrated that ADRA2A transgene expression and ADRA2A agonist inhibited PDAC cell invasion. Additionally, ADRA2A-high condition downregulated the basal-like/squamous gene expression signature, while upregulating the classical/progenitor gene expression signature in our PDAC patient cohort and PDAC cell lines. Metabolome analysis conducted on the PDAC cohort and cell lines revealed that elevated ADRA2A levels were associated with suppressed amino acid and carnitine/acylcarnitine metabolism, which are characteristic metabolic profiles of the classical/progenitor subtype. Collectively, our findings suggest that heightened ADRA2A expression induces transcriptome and metabolome characteristics indicative of classical/progenitor subtype with decreased disease aggressiveness in PDAC patients. These observations introduce ADRA2A as a candidate for diagnostic and therapeutic targeting in PDAC.